[ACE inhibitor or AT1 antagonist. Is there a differential therapy?]

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• ACE inhibitors and AT1 receptor antagonists are crucial for managing cardiovascular and renal diseases.
• Evidence-based medicine supports ACE inhibitors as first-line therapy for chronic heart failure, post-myocardial infarction, high cardiovascular risk, and type 1 diabetic nephropathy.

Purpose of the Study:

• To review the roles of ACE inhibitors and AT1 receptor antagonists in treating cardiovascular and renal conditions.
• To highlight the specific applications and limitations of these drug classes, including combination therapy and their use in hypertensive patients.

Main Methods:

• Review of evidence-based medicine criteria.
• Analysis of clinical trial data, including the LIFE study.
• Comparison of ACE inhibitors and AT1 antagonists in various patient populations.

Main Results:

• ACE inhibitors remain the primary choice for specific cardiovascular and renal conditions.
• AT1 antagonists are valuable alternatives when ACE inhibitors are not tolerated and are particularly effective in type 2 diabetic nephropathy.
• The LIFE study demonstrated the superiority of an AT1 antagonist over a beta-blocker in hypertensive patients with left-ventricular hypertrophy, especially with co-existing or impending diabetes.

Conclusions:

• ACE inhibitors are foundational for treating heart failure, post-MI, high-risk patients, and type 1 diabetic nephropathy.
• AT1 antagonists offer a vital alternative, particularly in cases of intolerance and for type 2 diabetic nephropathy.
• Combination therapy requires further investigation, but AT1 antagonists show promise in specific high-risk hypertensive populations.